Tractor Supply Maintains Margins While Funding Growth
Tractor Supply Company (NASDAQ: TSCO) held its fourth-quarter and fiscal-year 2024 earnings call on January 30, 2025. The company delivered record financial results and outlined its strategic growth initiatives. Management expressed confidence in its "Life Out Here 2030" strategy, which expands the company's total addressable market to $225 billion. For long-term investors, three key developments particularly stand out for understanding the company's future growth trajectory.
Tractor Supply's impressive customer metrics demonstrate strong loyalty and engagement despite challenging retail conditions, suggesting its differentiated rural lifestyle focus continues to resonate.
Front-line team member attrition is at a record low. Total active customer accounts are at record highs. High-value customer retention is at record levels. Customer service scores continue to hit all-time highs. Our Neighbor's Club, one of the largest loyalty programs in retail, continues to attract record levels of new customers, and we're exiting 2024 with all-time highs in both retention rates and retained customer counts.
Neighbor's Club membership now exceeds 38 million and represents a record 80% of sales. The program continues to drive deeper customer relationships and increased cross-shopping, with its Petsense shoppers cross-shopping Tractor Supply at "an impressive rate of 50%, an increase of nearly 3 points year-over-year."
The Allivet acquisition represents a significant push into the pet medication space, providing entry into a $15 billion market that complements Tractor Supply's existing pet business.
The acquisition of Allivet expands our total addressable market by $15 billion to $225 billion. Allivet has a proven platform to make pet ownership easier by providing convenient access to brand-name medications, expert pharmacy advice, and convenient reordering with its AutoShip program.
This strategic acquisition not only expands Tractor Supply's total addressable market but is expected to contribute more than $100 million to net sales in 2025 and be accretive to earnings. Management sees long-term potential for Allivet to match or exceed Tractor Supply's operating margins as the integration progresses.
Tractor Supply is strategically investing in new growth initiatives while offsetting these costs through gross margin expansion, allowing the company to maintain consistent operating margins.
We forecast the gross margin expansion to be offset by SG&A deleverage due to a couple of primary factors. First, depreciation and amortization is anticipated to increase about 10% with a higher growth rate in the first half as compared to the second half of the year. ... Second, we're investing in our Life Out Here 2030 strategic initiatives. In order to launch our direct sales and final-mile initiatives, we're planning a net investment of about 15 to 20 basis points of operating margin into these exciting opportunities for growth.
The company expects modest gross margin expansion of 20 to 40 basis points in 2025, driven by supply chain efficiencies and effective cost management. However, this improvement will be balanced against increased SG&A costs for strategic initiatives, resulting in an operating margin forecast of 9.6% to 10%, centered around 2024's performance.
With new store growth accelerating to 90 locations in 2025, the Allivet acquisition expanding the addressable market, and strategic investments in direct sales and final-mile delivery, Tractor Supply appears well-positioned to continue executing on its long-term growth strategy. Management is particularly focused on supply chain optimization, enhancing localization capabilities, integrating Allivet's pet medication business for Neighbor's Club members, and launching both direct sales and final-mile delivery initiatives.
As CFO Kurt Barton emphasized, "We have a long track record of successfully managing through diverse market conditions. The needs-based nature of our business, combined with our deep understanding of these dynamics, allows us to proactively adapt to the market conditions."
Before you buy stock in Tractor Supply, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tractor Supply wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $699,020!*
Now, it's worth noting Stock Advisor's total average return is 863% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of March 3, 2025
David Kretzmann has positions in Tractor Supply. The Motley Fool has positions in and recommends Tractor Supply. The Motley Fool has a disclosure policy.
Tractor Supply Maintains Margins While Funding Growth was originally published by The Motley Fool
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the following link: The event and accompanying slides can also be accessed by visiting the investor relations section of the company's website at An archived webcast will be available on the company's website following the event. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge (GC) induced symptoms. FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099). The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035). Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects. The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo. Gluten challenge induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain and abdominal bloating) reported during the 16 day gluten challenge from patient diaries/AE collection demonstrated a 42% benefit for FB102 treated subject (4.0 events per subject) compared to placebo (6.9 events per subject). There were no dropouts in the study. Treatment emergent adverse events (TEAE) were primarily mild (grade 1) with no grade 3 or higher SAEs reported in the FB102 arm. 'We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team. Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study. The Phase 2 celiac disease study is initiating with a topline readout expected in 2026.' said Paul Wagner, Ph.D. CEO and Chairperson of Forte Biosciences. 'These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes. We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026.' About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward-Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding Forte's beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102, the expected timeline for the Phase 2 celiac study and related readout, and the expected timing of topline results for the FB102 vitiligo study. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte's ability to obtain sufficient additional capital to continue to advance Forte's product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte's product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials; the risk that results from preclinical and the Phase 1b trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte's business and operating results is contained in Forte's Quarterly Report on Forms 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc.
Yahoo
39 minutes ago
- Yahoo
Is Fox Stock Outperforming the Nasdaq?
New York-based Fox Corporation (FOX) operates as a news, sports, and entertainment company in the United States. With a market cap of $22.8 billion, the company operates through Cable Network Programming, Television, Credible, and The FOX Studio Lot segments. Companies worth $10 billion or more are generally described as "large-cap stocks." FOX fits right into that category, with its market cap exceeding the threshold, reflecting its substantial size and influence in the competitive industry of entertainment. FOX benefits from being one of the largest cable TV networks in the United States, offering a wide range of content. Robotaxis, Powell and Other Key Things to Watch this Week Make Over a 2.4% One-Month Yield Shorting Nvidia Out-of-the-Money Puts Is Quantum Computing (QUBT) Stock a Buy on This Bold Technological Breakthrough? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! FOX currently trades 7.8% below its all-time high of $55 recorded on Mar. 3. FOX's stock has gained 2.7% over the past three months, notably underperforming the Nasdaq Composite's ($NASX) 9.9% uptick during the same time frame. In the long term, FOX stock has surged 10.9% on a YTD basis, outperforming the Nasdaq's marginal increase. Moreover, shares of FOX soared 59% over the past 52 weeks, also outperforming Nasdaq's 9.7% returns over the same period. To confirm its bullish trend, FOX has been trading above its 200-day moving average for the past year and also above its 50-day moving average since mid-May. FOX shares rose 4.3% following the release of its better-than-expected Q3 earnings on May 12. The company's total revenues increased 26.8% year-over-year to $4.4 billion, mainly driven by a robust growth in the revenue of its affiliate fee, advertising, and other components, and also surpassed the Street's estimates. Its adjusted EBITDA, however, decreased 3.9% to $856 million, caused by an increase in expenses due to higher sports programming rights amortization and production costs driven by the broadcast of Super Bowl LIX and higher digital content and marketing costs. FOX's adjusted earnings increased marginally year-over-year to $1.09 and surpassed the consensus estimates by 14.6%. Its rival, News Corporation (NWSA), has gained 2.9% in 2025 and 5.4% over the past year, underperforming FOX. Among the 13 analysts covering the FOX stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $54.92 suggests an 8.2% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Business Wire
43 minutes ago
- Business Wire
Dot Ai to Begin Trading on Nasdaq Stock Market
LAS VEGAS--(BUSINESS WIRE)--SEE ID, Inc., doing business as Dot Ai (Nasdaq: DAIC) ('Dot Ai'), a pioneering startup at the forefront of asset intelligence technology, today announced that shares of its Class A common stock and warrants will commence trading on the Nasdaq Stock Market under the ticker symbols 'DAIC' and 'DAICW,' respectively, on June 23, 2025. 'We're thrilled to finalize our listing and to become a publicly traded company,' said Ed Nabrotzky, Co-founder and CEO of Dot Ai. 'Leveraging state-of-the-art artificial intelligence engines, the Internet of Things, and our patented, proprietary and innovative software, hardware and cloud integration solutions, we are revolutionizing how companies all over the world manage their supply chains, logistics operations and operational security.' 'With access to the public markets, we look forward to executing on our growth plans, delivering on our product launches, including our recently announced Zero Infrastructure Mesh and more, and ramping up operations at our Puerto Rico manufacturing hub,' Mr. Nabrotzky continued. 'Furthermore, with partners like Würth Industry USA and additional key players to be announced in the coming months, we believe Dot Ai is well positioned to capitalize on the rapidly increasing demand for modern, next-gen technology that empowers comprehensive, efficient, secure and reliable supply chains across a variety of sectors.' Key Operational Highlights In December 2024, Dot Ai unveiled ZiM (Zero Infrastructure Mesh), a next-gen Internet of Things (IoT) tracking technology, to replace the outdated and expensive technologies that logistics operations have relied on for decades. ZiM is designed to offer an innovative asset management solution by securely gathering data at the edge of the enterprise. It can read both passive (battery free transponders) and active (battery powered beacons) to provide data for supervisory systems. The bridge can operate with its own battery power when mounted on moving racks or pallets or be hardwired to power for fixed installation in aisles or doorways. Puerto Rico Facility In May 2025, in partnership with Invest Puerto Rico ('Invest PR'), the island's business attraction organization, Dot Ai announced plans to establish its first hardware manufacturing operation in Barceloneta. The company chose Puerto Rico to benefit from U.S. jurisdictional protections, strong intellectual property enforcement and access to global markets from a domestic base. Dot Ai projects the facility will result in the creation of up to 200 full-time jobs over the next five years, subject to business conditions and operational scaling. Dot AI's new facility in Barceloneta will manufacture and globally distribute its patented IoT tracking systems, boosting Puerto Rico's reputation as a hub for cutting-edge technology and advanced manufacturing. Partnership with Wurth Industry USA In November 2024, Dot Ai and Würth Industry USA ('Würth'), a leading industrial distributor and division of the Würth Group, announced the execution of a five-year agreement to bring Dot Ai's advanced, AI-driven tracking solutions to Würth's customers. This access offers Würth unprecedented visibility into internal and customer premise operations and provides Dot Ai an exclusive partnership to serve Würth's manufacturing vertical. Under this agreement, Würth customers gain access to Dot Ai's state-of-the-art track and trace technology, including the ZiM Bridge, Industrial Passive asset tag solution (which requires no battery), and a cloud-based, AI platform that continually optimizes processes. These innovations are being seamlessly integrated with Würth's customized CPS ® kanban inventory management solutions, providing real-time data and increasing responsiveness to changing demands, resulting in unprecedented supply chain metrics and security. About Dot Ai At the heart of the technological revolution in asset management and security lies Dot Ai, a trailblazing SaaS service that is redefining the paradigms of asset intelligence, assurance and safety. By harnessing the power of IoT tracking technology, Dot Ai stands at the forefront of innovation, offering patented solutions that are not just advanced but transformative. Through relentless research and development, Dot Ai has pioneered a suite of technologies that empower organizations to not only streamline their logistics and supply chain processes but also bolster operational security to unprecedented levels. Leveraging state-of-the-art AI engines, cutting-edge 5G RF and BLE technology, and seamless cloud integrations, Dot Ai transcends traditional boundaries, offering real-time asset visibility and predictive analytics that integrate effortlessly with existing infrastructure. This is not just technology; it's a vision for a more secure, efficient, and connected world. Discover more about how Dot Ai is leading the charge in asset intelligence by visiting Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, including the statements regarding the anticipated timing to commence trading on the Nasdaq Stock Market, plans regarding the execution of its growth plans, expectations regarding its ZiM product launch and its Puerto Rico Facility expansion. All forward-looking statements are based on ShoulderUp's current expectations and beliefs concerning future developments and their potential effects on ShoulderUp, SEE ID or any successor entity thereof. Forward-looking statements are based on various assumptions, whether or not identified in this press release, and are subject to risks and uncertainties. These forward-looking statements are not intended to serve as a guarantee of future performance. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) risks that the transaction and listing disrupt current plans and operations of SEE ID, (ii) costs related to the transaction and the failure to realize anticipated benefits of the transaction or to realize estimated pro forma results and underlying assumptions, (iii) the risk that SEE ID and its current and future collaborators are unable to successfully develop and commercialize SEE ID's products or services, or experience significant delays in doing so, (iv) the risk that SEE ID may need to raise additional capital to execute its business plan, which many not be available on acceptable terms or at all, (v) the risk that the post-combination company experiences difficulties in managing its growth and expanding operations. The foregoing list of factors is not exhaustive; (vi) competition, the ability of SEE ID to grow and manage growth profitably, and retain its management and key employees; (vii) changes in applicable laws or regulations; and (viii) weakness in the economy, market trends, uncertainty and other conditions in the markets in which SEE ID operates, and other factors beyond its control, such as inflation or rising interest rates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the S-4 Registration Statement and proxy statement/prospectus discussed above and other documents filed or to be filed by ShoulderUp, SEE ID and/or any successor entity thereof from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ShoulderUp assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
